Revolution Medicines, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark A. Goldsmith
- Full Time Employees
- 616
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 700 Saginaw Drive Redwood City CA United States of America 94063
- IPO Date
- Feb 13, 2020
- CIK
- 0001628171
- Website
- revmed.com
- Similar Companies
- Business
- Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for patients with RAS-addicted cancers, which represent approximately 30% of human cancers; its research and development pipeline centers on proprietary RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including the pan-RAS inhibitor daraxonrasib (RMC-6236), the RAS(ON) G12C-selective inhibitor elironrasib (RMC-6291), and the RAS(ON) G12D-selective inhibitor zoldonrasib (RMC-9805). These inhibitors target previously undruggable frontier targets in the RAS pathway and mTOR signaling through tri-complex mechanisms to enhance drug-target engagement and overcome resistance. The company operates primarily in the United States with global clinical development activities and serves patients and healthcare providers in oncology. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines leverages its RAS(ON) drug discovery platform to advance late-stage programs. In June 2025, the company entered a transformative $2 billion funding arrangement with Royalty Pharma, comprising up to $1.25 billion in synthetic royalty financing (with $250 million upfront) on daraxonrasib and up to $750 million in senior secured debt to support global development, Phase 3 trials in pancreatic cancer and non-small cell lung cancer, commercialization, and pipeline expansion; this partnership enables Revolution Medicines to retain full control over its programs while advancing multiple Phase 3 trial launches. Recent updates include progress on daraxonrasib's Phase 3 readiness and a technology collaboration with Iambic announced in November 2025 to further enhance its RAS inhibitor portfolio.
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
Small-Cap ETF Showdown: Schwab's SCHA vs. iShares' IJR
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
US FDA authorizes early access to Revolution's pancreatic cancer pill
Which Is the Better Small-Cap ETF, Vanguard's VB or iShares' ISCB?
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Vanguard vs. Schwab: Which Small-Cap ETF Belongs in Your Portfolio?